ASB Consultores’s Ginkgo Bioworks DNA Stock Holding History

ASB Consultores’s Portfolio DNA Stock Details DNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-377	Closed	-$17.5K	–	230
2024 Q1	$17.5K	Buy	+377	New	+$19.5K	﹤0.01%	292
2023 Q4	–	Sell	-276	Closed	-$20K	–	125
2023 Q3	$20K	Buy	276 +2	+0.7%	+$160	0.01%	140
2023 Q2	$20.4K	Hold	274	–	–	0.01%	180
2023 Q1	$14.6K	Hold	274	–	–	0.01%	185
2022 Q4	$18.5K	Buy	+274	New	+$25.2K	0.01%	191

Other funds holding DNA

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

ACG

Anchorage Capital Group New York $450M AUM 41.75% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Legal & General Group London, United Kingdom $480B AUM 42.84% 1-Year Est. Return

GCM

Glenview Capital Management New York $5.49B AUM 46.89% 1-Year Est. Return

SIAU

SB Investment Advisers (UK) London, United Kingdom $7.66B AUM 20.12% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

ASB Consultores's DNA Position: Q2 2024 in Review

ASB Consultores sold out of Ginkgo Bioworks (DNA) in Q2 2024, closing a stake of 377 shares — an estimated $17.5K sold.

ASB Consultores first reported a position in DNA in Q4 2022 and held it in 5 quarters. The position peaked at $20.4K in Q2 2023. 313 funds tracked by Wall St. Rank hold DNA as of Q2 2024.

ASB Consultores reported no remaining Ginkgo Bioworks position as of Q2 2024 after selling out during the quarter.
ASB Consultores sold 377 Ginkgo Bioworks shares in Q2 2024, an estimated $17.5K.
ASB Consultores first reported a position in Ginkgo Bioworks in Q4 2022 and held it in 5 quarters.
ASB Consultores's Ginkgo Bioworks position peaked at $20.4K in Q2 2023.
313 funds tracked by Wall St. Rank held Ginkgo Bioworks as of Q2 2024.

Based on ASB Consultores's 13F filing for Q2 2024, filed 12 Aug 2024.